No Benefit to Extending Bevacizumab in Ovarian Cancer No Benefit to Extending Bevacizumab in Ovarian Cancer
Maurie Markman, MD, discusses results from a pragmatic clinical trial regarding extended frontline treatment with bevacizumab in patients with ovarian cancer.Medscape Oncology
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news
More News: Avastin | Cancer | Cancer & Oncology | Clinical Trials | Hematology | Ovarian Cancer | Ovaries